

SCHIERMEIER ANDREW

Form 3

April 27, 2018

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â SCHIERMEIER ANDREW

(Last)

(First)

(Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

04/20/2018

3. Issuer Name **and** Ticker or Trading Symbol  
Intellia Therapeutics, Inc. [NTLA]4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other  
(give title below) (specify below)

See Remarks

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
☒ Form filed by One Reporting  
Person  
☐ Form filed by More than One  
Reporting PersonC/O INTELLIA  
THERAPEUTICS, INC.,Â 40  
ERIE STREET, SUITE 130

(Street)

CAMBRIDGE,Â MAÂ 02139

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)Date  
ExercisableExpiration  
Date3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

Title

Amount or  
Number of4. Conversion  
or Exercise  
Price of  
Derivative  
Security5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

# Edgar Filing: SCHIERMEIER ANDREW - Form 3

|                             |       |            |              | Shares  |           | or Indirect<br>(I)<br>(Instr. 5) |   |
|-----------------------------|-------|------------|--------------|---------|-----------|----------------------------------|---|
| Stock Option (Right to Buy) | Â (1) | 01/02/2027 | Common Stock | 150,000 | \$ 13.48  | D                                | Â |
| Stock Option (Right to Buy) | Â (2) | 12/11/2027 | Common Stock | 27,500  | \$ 18.295 | D                                | Â |
| Stock Option (Right to Buy) | Â (3) | 01/02/2027 | Common Stock | 15,000  | \$ 13.48  | D                                | Â |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |               |       |
|---|---------------|-----------|---------------|-------|
|   | Director      | 10% Owner | Officer       | Other |
| SCHIERMEIER ANDREW<br>C/O INTELLIA THERAPEUTICS, INC.<br>40 ERIE STREET, SUITE 130<br>CAMBRIDGE, MA 02139 | Â             | Â         | Â See Remarks | Â     |

## Signatures

/s/Jose Rivera,  
Attorney-In-Fact

04/25/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option was granted on January 3, 2017 with respect to 150,000 shares of Common Stock, with 25% vesting on January 3, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

(2) This option was granted on December 12, 2017 with respect to 27,500 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

(3) This option is fully vested.

Â

### Remarks:

Title:Â Â ExecutiveÂ ViceÂ President,Â CorporateÂ Strategy  
ExhibitÂ 24Â PowerÂ ofÂ AttorneyÂ (filedÂ herewith)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.